Jill Wieser, MD
Dermatology · Maple Grove, MNNPI 1902398779
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,745 of the $4,940 with a category attached, or 75.8%. 16 manufacturers reported payments, led by AstraZeneca at 27.5% of the total. Reporting peaked in 2019 at $1,483 and has fallen 69.1% since, to $458 in 2024. Among dermatology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $89.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$713
- Boehringer Ingelheim$582
- Regeneron Healthcare Solutions, Inc.$562
- Janssen Scientific Affairs, LLC$436
- E.r. Squibb & Sons, L.L.C.$247
- plus $1K from 10 others
Across 8 payments — averaging $203.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
What the payments were for
- Travel & lodging$1,02321%
- Food & beverage$3,74576%
- Education$1723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $1,358 |
| AbbVie | 9 | $713 |
| Boehringer Ingelheim | 9 | $582 |
| Regeneron Healthcare Solutions, Inc. | 5 | $562 |
| Janssen Scientific Affairs, LLC | 4 | $436 |
| E.r. Squibb & Sons, L.L.C. | 2 | $247 |
| UCB, Inc. | 4 | $238 |
| Incyte Corporation | 3 | $175 |
| Mimedx Group, Inc. | 1 | $131 |
| Krystal Biotech Inc | 1 | $122 |
| Amgen | 1 | $115 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $109 |
| Johnson & Johnson | 1 | $100 |
| Tactile Systems Technology Inc | 1 | $19 |
| Sanofi | 1 | $18 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,940 in reported general payments places this provider in the 90th percentile of 273 dermatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 55 | $1,124 |
| Clobetasol Propionate | 27 | $676 |
| Triamcinolone Acetonide | 30 | $272 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Maple Grove
- Ronda FarahMaple Grove$18K
- Kristina ShafferEagan$538K
- Margareth Pierre-LouisMinneapolis$439K
- Maria HordinskyMinneapolis$85K
- Afsaneh AlaviRochester$71K
- Todd SeelhammerSaint Paul$63K
- Brittney SchultzMinneapolis$52K
- David PearsonMinneapolis$46K
- Phillip EckerWayzata$31K
- Noah GoldfarbMinneapolis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.